March 1997

Apolipoprotein E in Cerebrospinal Fluid in 85-Year-Old SubjectsRelation to Dementia, Apolipoprotein E Polymorphism, Cerebral Atrophy, and White Matter Lesions

Author Affiliations

From the Department of Psychiatry, Sahlgrenska Hospital (Dr Skoog), and the Unit of Neurochemistry, Department of Clinical Neuroscience, Mölndal Hospital (Ms Hesse and Drs Fredman and Blennow), Institute of Clinical Neuroscience, and the Department of Radiology, Östra Hospital (Drs Andreasson and Palmertz), Göteborg University, Göteborg, Sweden.

Arch Neurol. 1997;54(3):267-272. doi:10.1001/archneur.1997.00550150029012

Objective:  To further elucidate the pathogenetic role of apolipoprotein E (Apo E) in degenerative brain disorders, we analyzed cerebrospinal fluid (CSF) levels of Apo E in 85-year-old subjects with dementia disorders.

Design:  Survey.

Setting:  Community.

Participants:  Population-based sample of 27 demented (12 with Alzheimer disease [AD]; 13, vascular dementia [VAD]; and 2, other types of dementia) and 35 nondemented individuals.

Main Outcome Measures:  Cerebrospinal fluid levels of Apo E, Apo E polymorphism, and brain atrophy and white matter lesions (WMLs) measured by computed tomography (CT) of the brain. Dementia was defined according to Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised criteria; AD, National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria; and VAD, National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neuroscience criteria.

Results:  The mean (±SD) CSF levels of Apo E were lower in the AD (2.6±1.5 mg/L; P<.02) and VAD groups (2.5±0.9 mg/L; P<.002) than in the nondemented group (3.8±1.7 mg/L). Cerebrospinal fluid levels of Apo E decreased with increasing severity of dementia and with increasing temporal cortical and central frontal atrophy. In nondemented individuals, CSF levels of Apo E decreased with increasing degree of WMLs. Cerebrospinal fluid levels of Apo E were not influenced by the Apo E4 isoform.

Conclusions:  Whether our finding of an association between low CSF levels of Apo E and dementia disorders (both degenerative, such as AD, and vascular, such as VAD) is related to the pathogenesis of these disorders or is a secondary consequence of the disease process remains to be established. Although statistical correlations do not give direct evidence of causal relations, the correlations between CSF level of Apo E and severity of dementia and cortical atrophy suggest that CSF level of Apo E follows the disease process.